Hypothyroidism News and Research RSS Feed - Hypothyroidism News and Research

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone to meet the body’s needs. Without enough thyroid hormone, many of the body’s functions slow down. About 5 percent of the U.S. population has hypothyroidism. Women are much more likely than men to develop hypothyroidism.
Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen to present data on Repatha (evolocumab) and observational studies at ESC Congress 2015

Amgen today announced that it will present six abstracts at the upcoming ESC Congress 2015, organized by the European Society of Cardiology, being held Aug. 29 – Sept. 2 in London. [More]
SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

SUNY Downstate Medical Center researchers identify ALPIM syndrome as new spectrum disorder

The relationship between mental and physical health is well established. But when mental and physical illnesses co-occur, patients' accounts of physical illness are sometimes arbitrarily discredited or dismissed by physicians. [More]
Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Spouses & Relatives Of Celiac Disease Patients At Risk For Autoimmune Diseases

Both spouses and first-degree relatives of patients with celiac disease are at increased risk of nonceliac autoimmune disease, according to a study in the July issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. This risk represents a mixture of genetic, environmental and ascertainment bias mechanisms. [More]
Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Biotin benefits ‘clinically relevant’ in progressive multiple sclerosis

Patients with progressive multiple sclerosis and their clinicians see clear improvements during treatment with a high dose of biotin, show further results from the phase III trial of the therapy. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck expand collaboration for Talimogene laherparepvec-KEYTRUDA combination study

Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]
‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

Results of postmarketing follow-up in Japanese patients confirm the efficacy and safety profile of sunitinib in advanced renal cell carcinoma. [More]
Subclinical hyperthyroidism linked to increased fracture risk

Subclinical hyperthyroidism linked to increased fracture risk

In an analysis that included more than 70,000 participants from 13 studies, subclinical hyperthyroidism was associated with an increased risk for hip and other fractures including spine, according to a study in the May 26 issue of JAMA. Subclinical hyperthyroidism is a low serum thyroid-stimulating hormone concentration in a person without clinical symptoms and normal thyroid hormone concentrations on blood tests. [More]
Hope For Heroes Foundation forms national alliance with USA Medical Card

Hope For Heroes Foundation forms national alliance with USA Medical Card

Hope For Heroes Foundation today announced the formation of a groundbreaking national alliance with USA Medical Card, a leading provider of free pharmacy discount cards. The new nationwide initiative benefiting Hope For Heroes will help fund programs that empower independence for our nation's disabled military veterans, police, firemen, and EMS professionals, and will help more people afford their prescriptions. [More]
Misperceptions about miscarriage are widespread, survey finds

Misperceptions about miscarriage are widespread, survey finds

A survey of more than 1,000 U.S. adults has found that misperceptions about miscarriage and its causes are widespread. Results of the survey, conducted by researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Health System, show that feelings of guilt and shame are common after a miscarriage and that most people erroneously believe that miscarriages are rare. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Low and high maternal thyroid hormone levels during pregnancy may affect infant's IQ

Low and high maternal thyroid hormone levels during pregnancy may affect infant's IQ

A new study finds that not only low but also high maternal thyroid hormone levels during early pregnancy may significantly lower the infant's IQ later in childhood. The study results, which will be presented Thursday at the Endocrine Society's 97th annual meeting in San Diego, suggest that the common practice of treating pregnant women who have mild thyroid hormone deficiency may pose unexpected risks to the developing baby's brain. [More]
Study finds link between fluoridated water and ADHD prevalence

Study finds link between fluoridated water and ADHD prevalence

"Artificial water fluoridation prevalence was significantly positively associated with ADHD prevalence," according to research published in Environmental Health (2/15), reports the Fluoride Action Network (FAN). [More]
Thyroid disease can affect woman's reproductive health

Thyroid disease can affect woman's reproductive health

Thyroid disease can have significant effects on a woman's reproductive health and screening for women presenting with fertility problems and recurrent early pregnancy loss should be considered, suggests a new review published today (23 January) in The Obstetrician & Gynaecologist. [More]
Alzheimer's drug Aricept (donepezil) linked to serious side effects

Alzheimer's drug Aricept (donepezil) linked to serious side effects

New warnings have been added to the prescribing information for the Alzheimer's drug Aricept (donepezil) advising of the risk of two rare but potentially serious conditions: muscle breakdown (rhabdomyolysis) and a neurological disorder called neuroleptic malignant syndrome (NMS). [More]
Research findings may lead to new treatment for hypothyroidism

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective. [More]
Long-term axitinib in RCC effective with ‘controllable’ toxicities

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests. [More]
Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Merck, known as MSD outside of Canada and the United States, announced today early study findings demonstrating that patients treated with pembrolizumab, the company's investigational anti-PD-1 cancer therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82). [More]
Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin often requires treatment

Congenital hypothyroidism of central origin should not be dismissed as a mild condition and is worth screening for, say researchers. [More]
Initial congenital hypothyroidism severity predicts later cortical abnormalities

Initial congenital hypothyroidism severity predicts later cortical abnormalities

Research suggests that the persistent cognitive defects seen in children with congenital hypothyroidism, despite optimal care, are associated with altered cortical thickness. [More]
Advertisement
Advertisement